EcoDrugPlus

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSSLDG00000007162
Gene Symbol: PSMA3
1 Cross references
237 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSSLDG00000007213
Gene Symbol: PSMA3
1 Cross references
235 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSSLDG00000023100
Gene Symbol: PSMA4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSSLDG00000007517
Gene Symbol: PSMA5
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSLDG00000018934
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSSLDG00000024100
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSSLDG00000021694
Gene Symbol: PSMB2
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSSLDG00000005782
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSLDG00000012398
Gene Symbol: PSMB4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSLDG00000021700
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSSLDG00000012460
Gene Symbol: PSMB8
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSSLDG00000003743
Gene Symbol: PSMC1
3 Cross references
282 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).